Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

3articles mentioning drugs

12drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: BMS-986353 ×

BMS-986353

This drug is selected. Its supporting articles are shown below.

BMS-9863533

Articles mentioning BMS-986353

3 articles · page 1 of 1

OC.57 Safety and efficacy of CD19 NEX-T® (BMS-986353), a chimeric antigen receptor (CAR) T cell therapy, in systemic sclerosis (SSc): findings from the breakfree-1 trial

jsrd · abstract · 2026-06-05 · 4 matching annotations

99.0%

BMS-986353 nintedanib severe refractory SSc NCT05869955 dcSSc SSc-ILD

… disease progression and improve long-term outcomes are needed. BMS-986353, a CD19-directed CAR T NEX-T cell therapy, showed early efficac…

PO:11:273 CD19 NEX-T® (BMS-986353), a chimeric antigen receptor (CAR) T cell therapy, for active SLE with inadequate response to glucocorticoids and at least 2 immunosuppressants: a phase 2 trial in progress

lupusscimed · abstract · 2026-03-01 · 4 matching annotations

97.4%

BMS-986353 glucocorticoids Systemic lupus erythematosus SLE CD19-directed CAR T cell therapy

… appropriateness of outcome measures, and lack of control group.BMS-986353 is a CD19-directed CAR T cell therapy, manufactured using the n…

S15:01 Safety and efficacy of CD19 NEX-T® (BMS-986353)—a CD19-directed chimeric antigen receptor (CAR) T cell therapy—for severe refractory systemic lupus erythematosus (SLE): breakfree-1 trial update

lupusscimed · abstract · 2026-03-01 · 4 matching annotations

97.6%

BMS-986353 DL1 DL2 SLE SLE-directed

…ableConclusions These findings demonstrate manageable safety of BMS-986353 and highlight its potential to drive immune reset, leading to s…